宁科生物
(600165)
| 流通市值：24.55亿 | | | 总市值：54.13亿 |
| 流通股本：7.33亿 | | | 总股本：16.16亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 274,368,872.09 | 117,651,934.46 | 444,481,369.66 | 327,352,388.72 |
| 营业收入 | 274,368,872.09 | 117,651,934.46 | 444,481,369.66 | 327,352,388.72 |
| 二、营业总成本 | 353,575,429.53 | 136,912,848.55 | 678,172,087.77 | 513,802,317.45 |
| 营业成本 | 290,891,645.87 | 108,514,246.4 | 533,176,976.34 | 409,763,870.78 |
| 税金及附加 | 4,356,548.67 | 2,242,644.05 | 9,507,897.72 | 6,800,292.41 |
| 销售费用 | 3,639,119.15 | 1,593,298.89 | 5,383,351.75 | 3,540,960.62 |
| 管理费用 | 27,939,896.94 | 11,878,592.35 | 64,143,360.51 | 44,084,583.51 |
| 研发费用 | 12,506,948.84 | 5,826,954.96 | 38,536,988.4 | 26,844,175.99 |
| 财务费用 | 14,241,270.06 | 6,857,111.9 | 27,423,513.05 | 22,768,434.14 |
| 其中:利息费用 | 14,174,716.66 | 2,151,913.42 | 27,474,796 | 22,837,250.54 |
| 其中:利息收入 | 293,014.55 | 212,849.28 | 151,701.68 | 18,855.16 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | - | - | 340,988,904.61 | - |
| 资产处置收益 | - | - | 3,657,114.21 | -435,018.83 |
| 资产减值损失(新) | -56,961,410.02 | -44,800,782.21 | -222,563,040.25 | -56,054,842.92 |
| 信用减值损失(新) | -21,067.07 | -175,299.27 | -3,064,337.55 | -3,085,190.87 |
| 其他收益 | 4,072,200.2 | 726,147.81 | 4,253,771.15 | 6,532,405.95 |
| 四、营业利润 | -132,116,834.33 | -63,510,847.76 | -110,418,305.94 | -239,492,575.4 |
| 加:营业外收入 | 23,118.25 | 5,700.21 | 78,691.61 | 152,960.11 |
| 减:营业外支出 | 346,123.98 | 72,955.21 | 47,636,703.86 | 42,442,742.26 |
| 五、利润总额 | -132,439,840.06 | -63,578,102.76 | -157,976,318.19 | -281,782,357.55 |
| 减:所得税费用 | -43,971.4 | 233,320.59 | 4,916,957.78 | -103,743.7 |
| 六、净利润 | -132,395,868.66 | -63,811,423.35 | -162,893,275.97 | -281,678,613.85 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -132,395,868.66 | -63,811,423.35 | -162,893,275.97 | -281,678,613.85 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -132,468,807.22 | -64,315,533.14 | -90,376,880.01 | -250,979,200.73 |
| 少数股东损益 | 72,938.56 | 504,109.79 | -72,516,395.96 | -30,699,413.12 |
| 扣除非经常损益后的净利润 | -132,778,626.09 | -64,419,777.08 | -386,818,768.39 | -211,648,645.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.08 | -0.04 | -0.06 | -0.37 |
| (二)稀释每股收益 | -0.08 | -0.04 | -0.06 | -0.37 |
| 九、综合收益总额 | -132,395,868.66 | -63,811,423.35 | -162,893,275.97 | -281,678,613.85 |
| 归属于母公司股东的综合收益总额 | -132,468,807.22 | -64,315,533.14 | -90,376,880.01 | -250,979,200.73 |
| 归属于少数股东的综合收益总额 | 72,938.56 | 504,109.79 | -72,516,395.96 | -30,699,413.12 |
| 公告日期 | 2026-08-29 | 2026-04-30 | 2026-04-24 | 2025-10-31 |
| 审计意见(境内) | | | 带强调事项段的无保留意见 | |